Overview

Phase Ib Study of Axatilimab in Combination With Olaparib in BRCA1/2 and PALB2- Associated Metastatic HER2-negative Breast Cancer

Status:
RECRUITING

Trial end date:
2029-03-01

Target enrollment:

Participant gender:

Summary

This research is being done to evaluate the safety and tolerability of the new drug, axatilimab, in combination with olaparib (a standard of care treatment) in Breast Cancer 1/2 genes (BRCA 1/2) and PALB2 associated HER2-negative metastatic breast cancer. The names of the study drugs involved in this study are: * Axatilimab (a type of antibody) * Olaparib (a type of PARP inhibitor)

Phase:

PHASE1

Details

Lead Sponsor:

Dana-Farber Cancer Institute

Collaborator:

Incyte Corporation

Treatments:

axatilimab
olaparib